Profiles of patients who may benefit from bupropion therapy Review article
Article Sidebar
Published:
Dec 31, 2024
Keywords:
depression, bupropione, dopamine
Main Article Content
Abstract
A growing number of data from experimental and clinical studies indicate that changes in dopaminergic neurotransmission may play an important role in both the pathophysiology and therapy of depression. Most antidepressants, regardless of the primary mechanism of action, ultimately lead – through dopaminergic and noradrenergic pathways – to a significant increase in dopamine activity in the nucleus accumbens and prefrontal cortex, but few of them have a direct effect on dopamine transmission. An example of such a drug is bupropion, which is a dopamine and norepinephrine reuptake inhibitor. This drug may be useful in depressive patients with predominant anergy, excessive sleepiness, anhedonia and psychomotor retardation, as well as in the case of drug resistance (as part of combined therapy) or sexual disorders induced or intensified by other antidepressants (especially selective serotonin reuptake inhibitors and venlafaxine). It has a favorable metabolic profile and can be used in patients with depression and obesity, as well as helps with nicotine addiction.
Article Details
How to Cite
Dudek, D. (2024). Profiles of patients who may benefit from bupropion therapy. Medycyna Faktow (J EBM), 17(4(65), 525-530. https://doi.org/10.24292/01.MF.0424.14
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007; 64: 327-37.
2. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008; 68(5): 653-89.
3. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA.15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13.
4. Rybakowski J. Czterdziestolecie choroby afektywnej sezonowej. Psychiatr Pol. 2024; 58(5): 747-59.
5. Golden RN, Gaynes BN, Ekstrom RD et al. The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. Am J Psychiatry. 2005; 162(4): 656-62.
6. Pjrek E, Friedrich ME, Cambioli L et al. The efficacy of light therapy in the treatment of seasonal affective disorder: A meta-analysis of randomized controlled trials. Psychother Psychosom. 2020; 89(1): 17-24.
7. Geoffroy PA, Schroder CM, Reynaud E et al. Efficacy of light therapy versus antidepressant drugs, and of the combination versus monotherapy, in major depressive episodes: A systematic review and meta-analysis. Sleep Med Rev. 2019; 48: 101213.
8. Gartlehner G, Nussbaumer-Streit B, Gaynes BN et al. Second-generation antidepressants for preventing seasonal affective disorder in adults. Cochrane Database Syst Rev. 2019; 3(3): CD011268.
9. Dudek D, Wasik A, Gorostowicz A et al. Otyłość i zaburzenia psychiczne. In: Obesitologia Kliniczna. Olszanecka-Glinianowicz M. (ed.). Alfa-medica Press, 2021: 449-76.
10. Butnoriene J, Bunevicius A, Norkus A et al. Depression but not anxiety is associated with metabolic syndrome in primary care based community sample. Psychoneuroendocrinology. 2014; 40: 269-76. https://doi.org/10.1016/j.psyneuen.2013.11.002.
11. de Sousa Rodrigues ME, Bekhbat M, Houser MC et al. Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice. Brain Behav. Immunity. 2017; 59: 158-72. https://doi.org/10.1016/j.bbi.2016.08.021.
12. Delanogare E. et al. Enriched environment ameliorates dexamethasone effects on emotional reactivity and metabolic parameters in mice. Stress. 2020; 44(23): 466-73. https://doi.org/10.1080/10253890.2020.17353.
13. Morris G, Puri BK, Walker AJ et al. Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders. Neurosci Biobehav Rev. 2019; 107: 862-82. https://doi.org/10.1016/j.neubiorev.2019.09.025.
14. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002; 10(7): 633-41.
15. Patel K, Allen S, Haque MN et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016; 6(2): 99-144.
16. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84: 1-11.
17. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009; 17(1): 30-9.
18. Jakima S, Lew-Starowicz M. Dysfunkcje seksualne w depresji. Warszawa 2010.
19. Taylor M, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomized controlled trial. J Affective Disorders. 2005; 88: 241-54.
20. Jeffferson J, Pradko J, Muir K. Bupropion for major depressive disorder pharmacokinetic and formulation considerations. Clin Ther. 2005; 27: 1685-95.
21. Williams JM, Steinberg ML, Griffiths KG et al. Smokers with behavioral health comorbidity should be designed a tabacco use disparity group. Am J Public Health. 2013; 103: 1549-55.
22. Cooper J, Mancusso SG, Borland R et al. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry. 2012; 46: 851-63.
23. Wojnar M, Wierzbiński P, Samochowiec J et al. Postępowanie w uzależnieniu od nikotyny u pacjentów z zaburzeniami psychicznymi – zalecenia Polskiego Towarzystwa Psychiatrycznego. Część II. Psychiatr Pol. 2024; 58(3): 419-31.
2. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008; 68(5): 653-89.
3. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA.15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13.
4. Rybakowski J. Czterdziestolecie choroby afektywnej sezonowej. Psychiatr Pol. 2024; 58(5): 747-59.
5. Golden RN, Gaynes BN, Ekstrom RD et al. The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. Am J Psychiatry. 2005; 162(4): 656-62.
6. Pjrek E, Friedrich ME, Cambioli L et al. The efficacy of light therapy in the treatment of seasonal affective disorder: A meta-analysis of randomized controlled trials. Psychother Psychosom. 2020; 89(1): 17-24.
7. Geoffroy PA, Schroder CM, Reynaud E et al. Efficacy of light therapy versus antidepressant drugs, and of the combination versus monotherapy, in major depressive episodes: A systematic review and meta-analysis. Sleep Med Rev. 2019; 48: 101213.
8. Gartlehner G, Nussbaumer-Streit B, Gaynes BN et al. Second-generation antidepressants for preventing seasonal affective disorder in adults. Cochrane Database Syst Rev. 2019; 3(3): CD011268.
9. Dudek D, Wasik A, Gorostowicz A et al. Otyłość i zaburzenia psychiczne. In: Obesitologia Kliniczna. Olszanecka-Glinianowicz M. (ed.). Alfa-medica Press, 2021: 449-76.
10. Butnoriene J, Bunevicius A, Norkus A et al. Depression but not anxiety is associated with metabolic syndrome in primary care based community sample. Psychoneuroendocrinology. 2014; 40: 269-76. https://doi.org/10.1016/j.psyneuen.2013.11.002.
11. de Sousa Rodrigues ME, Bekhbat M, Houser MC et al. Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice. Brain Behav. Immunity. 2017; 59: 158-72. https://doi.org/10.1016/j.bbi.2016.08.021.
12. Delanogare E. et al. Enriched environment ameliorates dexamethasone effects on emotional reactivity and metabolic parameters in mice. Stress. 2020; 44(23): 466-73. https://doi.org/10.1080/10253890.2020.17353.
13. Morris G, Puri BK, Walker AJ et al. Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders. Neurosci Biobehav Rev. 2019; 107: 862-82. https://doi.org/10.1016/j.neubiorev.2019.09.025.
14. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002; 10(7): 633-41.
15. Patel K, Allen S, Haque MN et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016; 6(2): 99-144.
16. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84: 1-11.
17. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009; 17(1): 30-9.
18. Jakima S, Lew-Starowicz M. Dysfunkcje seksualne w depresji. Warszawa 2010.
19. Taylor M, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomized controlled trial. J Affective Disorders. 2005; 88: 241-54.
20. Jeffferson J, Pradko J, Muir K. Bupropion for major depressive disorder pharmacokinetic and formulation considerations. Clin Ther. 2005; 27: 1685-95.
21. Williams JM, Steinberg ML, Griffiths KG et al. Smokers with behavioral health comorbidity should be designed a tabacco use disparity group. Am J Public Health. 2013; 103: 1549-55.
22. Cooper J, Mancusso SG, Borland R et al. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry. 2012; 46: 851-63.
23. Wojnar M, Wierzbiński P, Samochowiec J et al. Postępowanie w uzależnieniu od nikotyny u pacjentów z zaburzeniami psychicznymi – zalecenia Polskiego Towarzystwa Psychiatrycznego. Część II. Psychiatr Pol. 2024; 58(3): 419-31.